U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07014917) titled 'Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL' on May 05.
Brief Summary: This is a randomized Phase II study of intermittent versus continuous venetoclax therapy with Acalabrutinib in previously untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
CLL Variant
Intervention:
DRUG: Venetoclax
intermittent venetoclax (7days administration per cycle) + acalabrutinib
DRUG: Acalabrutinib
intermittent venetoclax (7days administration per cycle) + acalabrutinib
DRU...